Neoplastic transformation of human small airway epithelial cells induced by arsenic

Molecular Medicine

Volumn 14, Issue 1-2, 2008, Pages 2-10

  Wen, Gengyun ^a   Calaf, Gloria M ^a,b   Partridge, Michael A ^a   Echiburú Chau, Carlos ^b   Zhao, Yongliang ^a   Huang, Sarah ^a   Chai, Yunfei ^a   Li, Bingyan ^a,c   Hu, Burong ^a   Hei, Tom K ^a  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSIDAD DE TARAPACÁ   (Chile)

^c SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; ARSENITE SODIUM; ONCOPROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; ARSENOUS ACID DERIVATIVE; MYC PROTEIN; PROTEIN C FOS; PROTEIN P21; PROTEIN P53; SODIUM DERIVATIVE; TELOMERASE; TERT PROTEIN, HUMAN; UNCLASSIFIED DRUG;

AIRWAY; ARTICLE; CARCINOGENESIS; CHROMOSOME ABERRATION; CONTROLLED STUDY; DNA REPAIR; DNA SYNTHESIS; EPITHELIUM CELL; FLOW CYTOMETRY; GENE AMPLIFICATION; GENOMIC INSTABILITY; GENOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE; NEOPLASM; ONCOGENE C FOS; ONCOGENE C MYC; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METABOLISM; MICRONUCLEUS; PATHOLOGY; RESPIRATORY TRACT MUCOSA;

ARSENITES; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; HUMANS; MICRONUCLEI, CHROMOSOME-DEFECTIVE; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS P21(RAS); RESPIRATORY MUCOSA; SODIUM COMPOUNDS; TELOMERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 40349090035     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2007-00090.Wen     Document Type: Article

References (47)

1. Navarro Silvera SA, Rohan TE. (2007) Trace elements and cancer risk: a review of the epidemiologic evidence. Cancer Causes Control 18:7-27.
2. Chan P, Huff JE. (1997) Arsenic carcinogenesis in animals and in humans: mechanistic, experimental, and epidemiological evidence. Environ. Carcinog. Ecotox. Rev. 15:83-122.
3. Huang C, Ke Q, Costa M, Shi X. (2004) Molecular mechanisms of arsenic carcinogenesis. Mol. Cell Biochem. 255:57-66.
4. Yager JW, Wiencke JK. (1993) Enhancement of chromosomal damage by arsenic: implications for mechanism. Environ. Health. Perspect. 101:79-82.
5. Zhang JJ, Smith KR. (2007) Household air pollution from coal and biomass fuels in China: measurements, health impacts, and interventions. Environ. Health Perspect. 115:848-55.
6. Shi HL, Shi XL, Liu KJ. (2004) Oxidative mechanism of arsenic toxicity and carcinogenesis. Mol. Cell Biochem. 255:67-78.
7. IARC (2004) Some drinking-water disinfectants and contaminants, including arsenic. Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC Monogr. Eval. Carcinog. Risks Hum. 84:1-477.
8. Hertz-Picciotto I, Smith SH, Holtzman D, Lipsett M, Alexeeff G. (1992) Synergism between occupational arsenic exposure and smoking in the induction of lung cancer. Epidemiology 3:23-31.
9. Kusiak RA, Ritchie AC, Muller AC, Springer J. (1993) Mortality from lung cancer in Ontario uranium miners. Br. J. Ind. Med. 50:920-7.
10. Ferreccio C, Gonzalez C, Milosavjlevic V, Marshall G, Sancha AM, Smith AH. (2000) Lung cancer and arsenic concentrations in drinking water in Chile. Epidemiology 11:673-9.
11. Lubin JH, Beane Freeman LE, Cantor KP. (2007) Inorganic arsenic in drinking water: an evolving public health concern. J. Natl. Cancer Inst. 99:906-7.
12. Marshall G, Ferreccio C, Yuan Y, Bates MN, Steinmaus C, Selvin S, Liaw J, Smith AH. (2007) Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J. Natl. Cancer Inst. 99:920-8.
13. Barrett JC, Lamb PW, Wang TC, Lee TC (1989) Mechanisms of arsenic-induced cell transformation. Biol. Trace Elem. Res. 21:421-9.
14. Wang Z, Rossman R. (1993) Stable and inducible arsenite resistance in Chinese hamster cells. Toxicol. Appl. Pharmacol. 118:80-6.
15. Lee TC, Oshimura M, Barrett JC. (1985) Comparison of arsenic-induced cell transformation, cytotoxicity, mutation and cytogenetic effects in Syrian hamster embryo cells in culture. Carcinogenesis 6:1421-6.
16. Landolph J. (1989) Molecular and cellular mechanisms of transformation of C3H/10T1/2 Cl 8 and diploid human fibroblasts by unique carcinogenic, nonmutagenic metal compounds: a review Biol. Trace Elem. Res. 21:459-67.
17. Nakamuro K, Sayato YC. (1981) Comparative studies of chromosomal aberration induced by trivalent and pentavalent arsenic. Mutat. Res. 88:73-80.
18. Natarajan AT, Boei JJ, Darroudi F, Van Diemen PC, Doulout F, Hande MP, Ramalho AT. (1996) Current cytogenetic methods for detecting exposure and effects of mutagens and carcinogens. Environ. Health Perspect. 104:445-58.
19. Lee TC, Tanaka N, Lamb PW, Gilmer TM, Barrett JC. (1988) Induction of gene amplification by arsenic. Science 241:79-81.
20. Vega L, Gonsebatt ME, Ostrosky-Wegman P. (1995) Aneugenic effect of sodium arsenite on human lymphocytes in vitro: an individual susceptibility effect detected. Mutat. Res. 334:365-73.
21. Keyse SM, Applegate LA, Tromvoukis Y, Tyrell RM. (1990) Oxidative stress leads to transcriptional activation of the human heme oxygenase gene in cultured skin fibroblasts. Mol. Cell Biol. 10:4967-72.
22. Huang CS, Ma WY, Li JX, Goranson A, Dong ZG. (1999) Requirement of Erk, but not JNK, for arsenite-induced cell transformation. J. Biol. Chem. 274:14595-601.
23. Meng ZQ, Meng NY. (2000) Effects of arsenic on blast transformation and DNA synthesis of human blood lymphocytes. Chemosphere 41:115-9.
24. Zhao CQ, Young MR, Diwan BA, Coogan TP, Walkes MP. (1997) Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc. Natl. Acad. Sci. U. S. A. 94:10907-12.
25. Bryan TM, Reddel RR. (1994) SV40-induced immortalization of human cells. Crit. Rev. Oncog. 5:331-57, 1994.
26. Willey JC, Broussoud A, Sleemi A, Bennett WO, Cerutti BP, Harris CC. (1991) Immortalization of normal human bronchial epithelial cells by human papillomaviruses 16 or 18. Cancer Res. 51:5370-7.
27. Achanzar WE, Brambila EM, Diwan BA, Webber MM, Waalkes MP. (2002) Inorganic arsenite-induced malignant transformation of human prostate epithelial cells. J. Natl. Cancer Inst. 94:1888-91.
28. Piao CQ, Liu L Zhao YL, Balajee AS, Suzuki M, Hei TK. (2005) Immortalization of human small airway epithelial cells by ectopic expression of telomerase. Carcinogenesis 26:725-31.
29. Fenech M. (2000) The in vitro micronucleus technique. Mutat. Res. 455:81-95.
30. Calaf GM, Hei TK. (2000) Establishment of a radiation and estrogen-induced breast cancer model. Carcinogenesis 21:769-76.
31. Hamada S, Nakajima K, Serikawa T, Hayashi M. (2003) The effect of aging on the results of the rat micronucleus assay. Mutagenesis 18:273-5.
32. Piao CQ, Hei TK. (2001) Gene amplification and microsatellite instability induced in tumorigenic human bronchial epithelial cells by alpha particles and heavy ions. Radiat. Res. 155:263-7.
33. Otto E, McCord S, Tlsty TD. (1989) Increased incidence of CAD gene amplification in tumorigenic rat lines as an indicator of genomic instability of neoplastic cells. J. Biol. Chem. 264:3390-6.
34. Wahl GM, Padgett RA, Stark GR. (1979) Gene amplification causes overproduction of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-aspartate-resistant hamster cells. J. Biol. Chem. 254:8679-89.
35. Lemoine FJ, Marriott SJ. (2002) Genomic instability driven by the human T-cell leukemia virus type I (HTLV-I) oncoprotein. Tax Oncogene 21:7230-4.
36. Chernova OB, Chernov MV, Ishizaka Y, Agarwal ML, Stark GR. (1998) MYC abrogates p53-mediated cell cycle arrest in N-(phosphonacetyl)-L-aspartate-treated cells, permitting CAD gene amplification. Mol. Cell Biol. 18:536-45.
37. Mondello C, Riboni R, Rady M, Giulotto E, Nuzzo F. (1995) Gene amplification in Chinese hamster DNA repair deficient mutants. Mutat. Res. 346:61-7.
38. Reichmann E. (1994) Oncogenes and epithelial cell transformation. Semin. Cancer Biol. 5:157-65.
39. Rosenwald IB. (2004) The role of translation in neoplastic transformation from a pathologist's point of view. Oncogene 23:3230-47.
40. Vogelstein B, Fearson ER, Bose JL. (1988) Genetic alteration during colorectal-tumor development. N. Engl. J. Med. 319:525-32.
41. Ling V Chambers AF, Harris JF, Hill RP. (1985) Quantitative genetic analysis of tumor progression. Cancer Metastasis Rev. 4:173-94.
42. Liu J, et al. (2006) Further studies on aberrant gene expression associated with arsenic-induced malignant transformation in rat liver TRL1215 cells. Toxicol. Appl. Pharmacol. 216:407-15.
43. Chen H, Liu J, Zhao CQ, Diwan BA, Merrick BA, Waalkes MP. (2001) Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation. Toxicol. Appl. Pharmacol. 175:260-8.
44. Menendez D, Mora G, Salazar AM, Ostrosky-Wegman P. (2001) ATM status confers sensitivity to arsenic cytotoxic effects. Mutagenesis 16:443-8.
45. Hsieh HJ, Chen JT, Hsieh SH, Jee GS, Chen CJ. (1994) Arsenic-related Bowen's disease and paraquat-related skin cancerous lesions showed no detectable ras and p53 gene alterations. Cancer Lett. 28:59-65.
46. Chanda S, et al. (2006) DNA hypermethylation of promoter of gene p53 and p16 in arsenic-exposed people with and without malignancy. Toxicol. Sci. 89:431-7.
47. Boonchai W, Walsh M, Cummings M, Chenevix-Trench G. (2000) Expression of p53 in arsenic-related and sporadic basal cell carcinoma. Arch. Dermatol. 136:195-8.